CGON 241220 22.50P (CGON241220P22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CGON241220P22500

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 2 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
GlobeNewswireDec 2 08:00 ET
One CG Oncology Insider Has Reduced Their Stake
Simply Wall StNov 26 08:09 ET
Express News | CG Oncology To Present At Society of Urologic Oncology (SUO) 25th Annual Meeting Dec. 4-6
BenzingaNov 20 08:14 ET
CG Oncology's Financial Results and Clinical Developments
TipRanksNov 13 23:42 ET
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Moomoo NewsNov 13 08:36 ET · Ratings
CG Oncology Analyst Ratings
BenzingaNov 13 07:02 ET · Ratings

Comments

Teo knows

Nov 25 08:57

$CG Oncology (CGON.US)$ fly

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

Apr 18 03:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...

Meltyy

Apr 1 02:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3...

Moomoo AI

Jan 26 10:59

CG Oncology's successful IPO hints at a possible resurgence of investor interest in biotech stocks, despite the sector's recent underperformance. This strong debut is viewed as a positive indicator for the sector's future.

Biotech's First IPO of 2024 Popped 96%. Good Times Could Be Ahead for the Stocks. -- Barrons.com